Mahidol University

ABVC BioPharma Provides Vitargus® Update

Retrieved on: 
Thursday, June 30, 2022
Cedars-Sinai Medical Center, FDA, Patient, Srinagarind Hospital, Ramathibodi Hospital, Case report form, Glut: Mastering Information Through the Ages, University of California, San Francisco, EC, Khon Kaen University, GLOBE, Ophthalmology, CNS, Company, San Francisco, Mahidol University, U.S. Securities and Exchange Commission, Forward-looking statement, Ethics committee, National Research Council, Trial of the century, CRF, Technology, University, CA, CREC, SEC, Risk, NASDAQ, Stanford University, Security (finance), Pharmaceutical industry

FREMONT, CA, June 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Vitargus® Phase II Clinical Study Protocol has been approved by the Central Research Ethics Committee (CREC) of The National Research Council of Thailand. The approval encompasses the study protocol as well as the Master Informed Consent Form (Master ICF), Case Report Form (CRF) and the Investigator’s Brochure (IB), along with other relevant documents.

Key Points: 
  • FREMONT, CA, June 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Vitargus Phase II Clinical Study Protocol has been approved by the Central Research Ethics Committee (CREC) of The National Research Council of Thailand.
  • ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development.
  • For Vitargus, the company intends to conduct the clinical trials through Phase III at various locations throughout the globe.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

The Agenda Is Set for the "Future of Functional Medicine Symposium" in Bangkok, May 20th

Retrieved on: 
Monday, May 9, 2022
Functional medicine, Summit, Fertility, Immune system, Regenerative medicine, National, GWS, Symposium, MICC, Public health, Cardiology, Wellness, Medicine, Biomarker, Mahidol University, Bumrungrad International Hospital, Quality of life, PR, Partnership, Alternative, Cancer, Hospital, Genomics, MD, Immersion, Health, Phyathai Hospitals Group, Efficiency, Phaya Thai, Science, CEO, Research, Future, Collection, MHG, Pharmaceutical industry, Renewable energy, Medical device, Symposia, Longevity

MIAMI, May 9, 2022 /PRNewswire-PRWeb/ -- The Global Wellness Summit (GWS), the foremost gathering of international leaders in the multitrillion-dollar global wellness economy, today announced that the agenda for the first "Future of Functional Medicine Symposium" is set. The event, created in partnership with Miskawaan Health Group (MHG), a global leader in functional medicine, takes place in Bangkok, Thailand on Friday, May 20th.

Key Points: 
  • The event, created in partnership with Miskawaan Health Group (MHG), a global leader in functional medicine, takes place in Bangkok, Thailand on Friday, May 20th.
  • The symposium's agenda illustrates the many new directions underway in this personalized, precise approach to healthcare and wellbeing.
  • Mart Maiprasert, MD, anti-aging and regenerative medicine specialist (Thailand), on: "Why Choose Integrative Wellness & Functional Medicine, Not Just Conventional Medicine?"
  • Over the past decade, the mainstream medical community and even pharma companies have been more accepting of functional medicine.

American Kidney Fund Awards Two Clinical Scientist in Nephrology Fellowships to Researchers Focused on Disparities in Kidney Transplants, Genetic Variants in Nephrotic Syndrome

Retrieved on: 
Thursday, March 10, 2022
Charity Navigator, Boston, Kidney, Urine, Disease management, Siriraj Hospital, University, Kidney disease, Risk, Research, Hope, MS, Damascus University - Faculty of Medicine, Platinum, Disorder, American Kidney Fund, Kidney transplantation, Health, Precision medicine, DO, Stanford University School of Medicine, Policy, Hospital, Osteopathic medicine in the United States, Mahidol University, Prevalence, GLOBE, Health equity, Nephrotic syndrome, Patient, Mass, Candid (organization), Therapy, AKF, Faculty, Genetics, Disease, McGill University, Bachelor of Science, Transplant, Fellow, Goal, Diagnosis, CEO, Pharmaceutical industry, Dentistry, Medicine, Nephrology, Brigham, MD, Medicine

Her project will examine the reasons for this disparity and evaluate alternative kidney allocation strategies that enhance access to well-matched kidney transplants.

Key Points: 
  • Her project will examine the reasons for this disparity and evaluate alternative kidney allocation strategies that enhance access to well-matched kidney transplants.
  • My research aims to understand the impact of genetic forms of nephrotic syndrome on adults with this disease.
  • The American Kidney Fund (AKF) fights kidney disease on all fronts as the nations leading kidney nonprofit.
  • With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF.

ABVC BioPharma Selects Additional Vitargus® Phase II Study Sites

Retrieved on: 
Wednesday, January 5, 2022
Safety, Retina, Pars plana, University, Ramathibodi Hospital, Company, Forward-looking statement, Patient, CA, Ophthalmology, San Francisco, Phase, Srinagarind Hospital, Risk, U.S. Securities and Exchange Commission, Security (finance), Mahidol University, Retinal detachment, NASDAQ, SEC, FDA, CNS, GLOBE, Technology, Effectiveness, Khon Kaen University, Cedars-Sinai Medical Center, Stanford University, Visual acuity, University of California, San Francisco, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Pharmaceutical industry

Fremont, CA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced two clinical sites in Thailand have been selected to participate in the Phase II clinical study of Vitargus®, the first bio-degradable vitreous substitute intended to facilitate retina re-attachment surgery. The new sites, located at the Ramathibodi Hospital at Mahidol University and the Srinagarind Hospital at Khon Kaen University, will join two planned Australian sites already selected to participate in the study. The Company expects the Thailand Food and Drug Administration (“FDA”) and the Australian Therapeutic Goods Administration to approve the study sites and principal investigators in Q1 of 2022 with first patient enrollments beginning during Q2 of 2022.

Key Points: 
  • Fremont, CA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced two clinical sites in Thailand have been selected to participate in the Phase II clinical study of Vitargus, the first bio-degradable vitreous substitute intended to facilitate retina re-attachment surgery.
  • The new sites, located at the Ramathibodi Hospital at Mahidol University and the Srinagarind Hospital at Khon Kaen University, will join two planned Australian sites already selected to participate in the study.
  • During the year, we intend to keep big pharma companies that have expressed an interest in distributing Vitargus apprised of the study data as it becomes available.
  • For Vitargus, the Company intends to conduct the clinical trials through Phase III at various locations throughout the globe.

Guangxi: Open Up New Prospects for Cooperation in Scientific and Technological Innovation With ASEAN

Retrieved on: 
Monday, September 27, 2021
Transfer, Technology, Internet, Ministry, Research, Chinese Academy of Sciences, Innovative Space-based Radar Antenna Technology, Chemical engineering, Federal Ministry of Science and Technology, Green finance and the Belt and Road Initiative, Collaborative innovation network, COVID-19, Mahidol University, Technology transfer, University, Cloud computing, Belt, Department, Renewable energy

NANNING, China, Sept. 27, 2021 /PRNewswire/ -- From September 9 to 13, the 9th Forum on China-ASEAN Technology Transfer and Collaborative Innovation was inaugurated in Nanning.

Key Points: 
  • NANNING, China, Sept. 27, 2021 /PRNewswire/ -- From September 9 to 13, the 9th Forum on China-ASEAN Technology Transfer and Collaborative Innovation was inaugurated in Nanning.
  • The China-ASEAN Technology Trading Platform and the Innovation Space for China-ASEAN Science and Technology Talents were officially launched at the conference.
  • In recent years, the Department of Science and Technology of Guangxi has made full use of the geographical advantage of Guangxi, i.e.
  • being adjacent to ASEAN countries, implemented "the Belt and Road" Science, Technology and Innovation Action Plan, strengthened the construction of China-ASEAN Technology Transfer Center (hereinafter referred to as "CATTC"), strived to open up a new situation in cooperation in scientific and technological innovation between Guangxi and ASEAN.

Guangxi: Open Up New Prospects for Cooperation in Scientific and Technological Innovation With ASEAN

Retrieved on: 
Monday, September 27, 2021
Transfer, Technology, Internet, Ministry, Research, Chinese Academy of Sciences, Innovative Space-based Radar Antenna Technology, Chemical engineering, Federal Ministry of Science and Technology, Green finance and the Belt and Road Initiative, Collaborative innovation network, COVID-19, Mahidol University, Technology transfer, University, Cloud computing, Belt, Department, Renewable energy

NANNING, China, Sept. 27, 2021 /PRNewswire/ -- From September 9 to 13, the 9th Forum on China-ASEAN Technology Transfer and Collaborative Innovation was inaugurated in Nanning.

Key Points: 
  • NANNING, China, Sept. 27, 2021 /PRNewswire/ -- From September 9 to 13, the 9th Forum on China-ASEAN Technology Transfer and Collaborative Innovation was inaugurated in Nanning.
  • The China-ASEAN Technology Trading Platform and the Innovation Space for China-ASEAN Science and Technology Talents were officially launched at the conference.
  • In recent years, the Department of Science and Technology of Guangxi has made full use of the geographical advantage of Guangxi, i.e.
  • being adjacent to ASEAN countries, implemented "the Belt and Road" Science, Technology and Innovation Action Plan, strengthened the construction of China-ASEAN Technology Transfer Center (hereinafter referred to as "CATTC"), strived to open up a new situation in cooperation in scientific and technological innovation between Guangxi and ASEAN.

Hundreds of Educators, Policymakers & Technology Leaders Assemble to Discuss the Future of Education in Thailand

Retrieved on: 
Thursday, September 9, 2021

Thailand, Sept 10, 2021 - (ACN Newswire) - On 14-15 September 2021, EDUtech Thailand will bring together the entire Thai education ecosystem to discuss new strategies, pedagogies and innovations to help inspire the next generation.

Key Points: 
  • Thailand, Sept 10, 2021 - (ACN Newswire) - On 14-15 September 2021, EDUtech Thailand will bring together the entire Thai education ecosystem to discuss new strategies, pedagogies and innovations to help inspire the next generation.
  • Setting the tone for the event is an inspiring opening keynote address by Kalaya Sophonpanich, Deputy Minister of Ministry of Education, Thailand.
  • Headlining day 2 of the event is the exclusive keynote panel by lead by the Digital Economy Promotion Agency.
  • Prof. Dr. Noawanit Songkram, Faculty of Education, Chulalongkorn University, and Dr. Sommai Khantong, Deputy Director of Digital Innovation Development Department, Mahasarakham University.

Disruptive.Asia Comments on How Huawei and ONDE Are Helping Thailand Fight COVID-19 and Go Digital at the Same Time

Retrieved on: 
Monday, August 3, 2020
Telecommunications, Internet, Health, Infectious diseases, Consumer electronics, Hospitals, Technology, Mobile, Wireless, Hospitals in Thailand, Mahidol University, Telecommunications, Siriraj Hospital, Ramathibodi, Huawei, Siriraj

For example, in April 2020, MDES and Huawei deployed a solution for Ramathibodi Hospital and Siriraj Hospital that combines these technologies to diagnose COVID-19 cases.

Key Points: 
  • For example, in April 2020, MDES and Huawei deployed a solution for Ramathibodi Hospital and Siriraj Hospital that combines these technologies to diagnose COVID-19 cases.
  • Disruptive.Asia thinks the biggest benefit of applying digital technologies to fight the COVID-19 pandemic is that Thailand progresses towards the goal of becoming a digital economy: Thailand 4.0 has actually been accelerated.
  • Phase 3 will focus on finding ways to use digital technology for sustainable economic and social development, helping Thailand establish itself as a global digital leader.
  • Huawei and ONDE will continue to collaborate to help every sector utilize digital technologies to ensure the needs of Thai people are served by the digital economy.

Thailand BOI, University Network to Spur R&D Linkage with Industry

Retrieved on: 
Wednesday, August 21, 2019
Chakri dynasty, Orders, decorations, and medals of Thailand, Southeast Asia, Thailand, Mahidol Adulyadej, Khon Kaen, Mahidol University, Hospitals in Thailand, Austrian-South-East Asian Academic University Network

The agreement will stimulate collaboration inprivate sector demand-driven R&D activities, co-operative education programs and high-skilled workforce recruitment, the BOI said.

Key Points: 
  • The agreement will stimulate collaboration inprivate sector demand-driven R&D activities, co-operative education programs and high-skilled workforce recruitment, the BOI said.
  • The RUN alliance was setup by four institutions located in Bangkok, namely Chulalongkorn University, Kasetsart University, Thammasat University, Mahidol University, and another four located in major provincial cities, namely Chiang Mai University, Khon Kaen University, Prince of Songkla University and Naresuan University.
  • Thailand is targeting a further increase to 1.5 percent by 2021, as part of the Government's Thailand 4.0 policy which aims to drive economic growth through innovation.
  • The alliance has collaboration agreements with several international partners such as New Zealand's MacDiarmid Institute for Advanced Materials and Nanotechnology, Japan's Keio University, and Malaysia's Research University Network.

Thailand BOI, University Network to Spur R&D Linkage with Industry

Retrieved on: 
Wednesday, August 21, 2019
Chakri dynasty, Orders, decorations, and medals of Thailand, Southeast Asia, Thailand, Mahidol Adulyadej, Khon Kaen, Mahidol University, Hospitals in Thailand, Austrian-South-East Asian Academic University Network

The agreement will stimulate collaboration inprivate sector demand-driven R&D activities, co-operative education programs and high-skilled workforce recruitment, the BOI said.

Key Points: 
  • The agreement will stimulate collaboration inprivate sector demand-driven R&D activities, co-operative education programs and high-skilled workforce recruitment, the BOI said.
  • The RUN alliance was setup by four institutions located in Bangkok, namely Chulalongkorn University, Kasetsart University, Thammasat University, Mahidol University, and another four located in major provincial cities, namely Chiang Mai University, Khon Kaen University, Prince of Songkla University and Naresuan University.
  • Thailand is targeting a further increase to 1.5 percent by 2021, as part of the Government's Thailand 4.0 policy which aims to drive economic growth through innovation.
  • The alliance has collaboration agreements with several international partners such as New Zealand's MacDiarmid Institute for Advanced Materials and Nanotechnology, Japan's Keio University, and Malaysia's Research University Network.